Abbvie Inc (ABBV)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ABBV Giù? Forum Previsione Storia dei dividendi

Perché le azioni Abbvie Inc (ABBV) sono in ribasso?

Abbiamo notato un calo di 5.36% nelle azioni di Abbvie Inc (ABBV) durante la sessione di negoziazione di 2024-04-26. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!

2024-04-04:

Abbvie (ABBV) stock dropped by 5.32% following the company's revision of its full-year and Q1 guidance, reflecting an unfavorable impact on earnings. This marked the biggest intraday decline in more than five months for the North Chicago-based pharma giant.

Revised Guidance: AbbVie revised its full-year and Q1 2024 guidance for adjusted diluted earnings to $10.97–$11.17 and $2.18–$2.22 per share, respectively. This adjustment accounts for acquired in-process R&D and milestones expenses.
Impact on Earnings: The company stated that $164 million in acquired IPR&D and milestones expense for Q1 2024 would have a $0.08 unfavorable impact on GAAP and non-GAAP diluted earnings per share for the quarter.
Previous Guidance Adjustment: In February, AbbVie lowered its Q1 adjusted diluted EPS guidance to $2.26–$2.30, including a $0.42 per share dilutive impact related to its Immunogen acquisition and pending buyout deal with Cerevel Therapeutics (CERE). Despite this, the company reaffirmed its full-year adjusted diluted EPS guidance at $11.05–$11.25 for 2024.
Analysts' View: The correction made to the story clarified AbbVie's full-year earnings outlook, highlighting the importance of accurate financial reporting and its impact on stock performance.